• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

NATCO receives emergency-use approval for Baricitinib tablets for COVID-19 treatment

expresspharmaMay 07, 2021

Tag: NATCO , Baricitinib , COVID-19 , Remdesivir

Natco Pharma has received emergency-use approval for Baricitinib tablets – 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib, in combination with Remdesivir, is used for the treatment of COVID-19-positive patients.

NATCO receives emergency-use approval for Baricitinib tablets for COVID-19 treatment

Natco will be requesting a compulsory license based on emergency use and in light of the grave and serious public health emergency across India due to the pandemic. The company is ready to launch the product this week, so as to make it available to suffering patients across India.

Previous:Centre has so far provided over 16.54 crore vaccine doses to states/UTs for free

Next:Pfizer in talks with India over expedited approval for COVID-19 vaccine

Related News

Macrogen Consortium win tender for National Bio Big Data Project

PRNewswireDecember 23, 2024

Macrogen and Illumina Inc. (NASDAQ: ILMN) announced today that they are honoured to support the National Bio Big Data project by sequencing and analysing 145,952 Korean genomes.

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

NATCO receives emergency-use approval for Baricitinib tablets for COVID-19 treatment | Pharmasources.com

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Manulife Hong Kong today announced a new partnership with New Frontier Group, one of the leading healthcare service providers in Greater China, to introduce cashless services for eligible customers through New Frontier Group's subsidiary, Prosper Health.

You may like
More>>

Baricitinib

Baricitinib
Baricitinib Impurity 23

Baricitinib Impurity 23
Remdesivir

Remdesivir
Baricitinib Impurity 8

Baricitinib Impurity 8
Baricitinib

Baricitinib
Remdesivir

Remdesivir
Baricitinib Impurity 1

Baricitinib Impurity 1
Remdesivir

Remdesivir
Baricitinib API

Baricitinib API
Remdesivir Chloro compound

Remdesivir Chloro compound

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service